These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Search MEDLINE/PubMed
Title: [Significance of stereotactic biopsy for the management of WHO grade II supratentorial glioma]. Author: Muacevic A, Kreth FW. Journal: Nervenarzt; 2003 Apr; 74(4):350-4. PubMed ID: 12707704. Abstract: OBJECTIVE: The aim of this prospective study was to compare the diagnostic value of magnetic resonance imaging (MRI) and stereotactic biopsy in patients harboring WHO grade II gliomas. METHODS: Stereotactic biopsy was performed in 62 adult patients with low-signal, nonenhancing, space-occupying lesions on T1 MR imaging between 1998 and 2001. The results of histological analysis were compared to the preoperative imaging diagnoses. Any adverse perioperative sequel was considered as morbidity. Applied treatment strategies are described. RESULTS: Transient perioperative morbidity for the stereotactic approach was 4.8% (three patients), and there was no mortality or permanent morbidity. In four patients, neoplastic lesions could be excluded (gliosis: three patients, encephalitis: one), and WHO grade III gliomas were seen in five patients (14.8.% false positive rate of neurodiagnostic imaging). The diagnostic reliability of stereotactic biopsy was 96.8%. The following treatment strategies were initiated: microsurgery (17 patients), interstitial radiosurgery (12 patients), combination of microsurgery and interstitial radiosurgery (21 patients), external beam irradiation (six patients),and chemotherapy (two patients). Four patients were initially not treated. CONCLUSIONS: Diagnostic neuroimaging is not sufficient for the planning of rational treatment strategies in patients harboring WHO grade II gliomas. Frame-based stereotactic biopsy is a prerequisite for individualized treatment strategies.[Abstract] [Full Text] [Related] [New Search]